Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd.

J Viral Hepat. 2014 Apr;21(4):288-96. doi: 10.1111/jvh.12142.

2.

HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.

Hamers RL, Zaaijer HL, Wallis CL, Siwale M, Ive P, Botes ME, Sigaloff KC, Hoepelman AI, Stevens WS, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER)..

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d.

PMID:
23892239
3.

Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.

Lewin SR, Ribeiro RM, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ.

Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754.

4.

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.

Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ.

Hepatology. 2008 Oct;48(4):1062-9. doi: 10.1002/hep.22462.

PMID:
18697216
5.

Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.

Archampong TN, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Gillani FS, Yang H, Boamah I, Flanigan T, Kwara A.

BMC Infect Dis. 2016 Jan 13;16:14. doi: 10.1186/s12879-016-1342-4.

6.

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.

Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM.

J Viral Hepat. 2007 Mar;14(3):176-82.

PMID:
17305883
7.

Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.

Li Y, Xie J, Han Y, Wang H, Zhu T, Wang N, Lv W, Guo F, Qiu Z, Li Y, Du S, Song X, Thio CL, Li T.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):39-45. doi: 10.1097/QAI.0000000000000927.

PMID:
26745828
8.

Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.

Childs K, Joshi D, Byrne R, Bruce M, Carey I, Agarwal K, Taylor C.

AIDS. 2013 Jun 1;27(9):1443-8. doi: 10.1097/QAD.0b013e32836011c2.

PMID:
23435302
9.

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.

Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M.

J Antimicrob Chemother. 2005 Dec;56(6):1087-93.

10.

Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.

Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M.

J Viral Hepat. 2012 Nov;19(11):801-10. doi: 10.1111/j.1365-2893.2012.01601.x.

PMID:
23043387
11.

Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.

Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraqueiro G, Moucari R, Hamet G, Martinot-Peignoux M, Matheron S, Marcellin P.

Liver Int. 2012 Jan;32(1):93-101. doi: 10.1111/j.1478-3231.2011.02601.x.

PMID:
22097898
12.

Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.

Huang AJ, Núñez M.

J Int Assoc Provid AIDS Care. 2015 Jul-Aug;14(4):360-8. doi: 10.1177/2325957415586258.

PMID:
25999329
13.

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.

Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, Sasadeusz J, Revill PA, Littlejohn M, Hoy JF, Finlayson R, Ruxrungtham K, Saulynas M, Locarnini S, Thio CL.

Clin Infect Dis. 2013 May;56(9):e87-94. doi: 10.1093/cid/cit002.

14.

Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.

Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, Aberg JA.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):172-80. doi: 10.1097/QAI.0000000000000149.

15.

Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.

Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.

Antivir Ther. 2008;13(3):341-8.

PMID:
18572746
16.

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.

Bihl F, Martinetti G, Wandeler G, Weber R, Ledergeber B, Calmy A, Battegay M, Cavassini M, Vernazza P, Caminada AP, Rickenbach M, Bernasconi E; Swiss HIV Cohort Study..

BMC Gastroenterol. 2015 Jul 8;15:79. doi: 10.1186/s12876-015-0308-0.

17.

Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.

Wongprasit P, Manosuthi W, Kiertiburanakul S, Sungkanuparph S.

AIDS Patient Care STDS. 2010 Apr;24(4):205-9. doi: 10.1089/apc.2009.0322.

PMID:
20377434
18.

Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.

Núñez M, Ramos B, Díaz-Pollán B, Camino N, Martín-Carbonero L, Barreiro P, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Sep;22(9):842-8.

PMID:
16989608
19.

Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.

Mikulska M, Taramasso L, Giacobbe DR, Caligiuri P, Bruzzone B, Di Biagio A, Viscoli C.

J Med Virol. 2012 Sep;84(9):1340-3. doi: 10.1002/jmv.23338.

PMID:
22825811
20.

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.

Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T.

Lancet. 2001 Sep 1;358(9283):718-23.

PMID:
11551579
Items per page

Supplemental Content

Support Center